Kyverna Therapeutics (KYTX) Cash from Financing Activities (2023 - 2026)
Kyverna Therapeutics (KYTX) posted Cash from Financing Activities of -$101000.0 for Q1 2026, down 100.07% on a QoQ basis from $140.7 million in Q4 2025, and up 75.6% year-over-year from -$57515.8 in Q1 2025.
Kyverna Therapeutics (KYTX) Cash from Financing Activities (2023 - 2026) Analysis & Trends
Kyverna Therapeutics' Cash from Financing Activities history runs 4 years deep, the most recent figure standing at -$101000.0 for Q1 2026.
- Quarterly Cash from Financing Activities rose 75.6% year-over-year to -$101000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $141.5 million (up 10580.07% YoY) and the FY2025 annual result came in at $141.2 million, down 58.12% from the prior year.
- Cash from Financing Activities was -$101000.0 for Q1 2026 at Kyverna Therapeutics, down from $140.7 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $338.0 million in Q1 2024 and bottomed at -$1.4 million in Q4 2023.
- A 4-year average of $41.3 million and a median of -$144000.0 in 2023 frame the typical range for Cash from Financing Activities.
- Peak annual rise in Cash from Financing Activities reached 234856.25% in 2024, while the deepest fall reached 102.28% in 2024.
- Kyverna Therapeutics' Cash from Financing Activities stood at -$1.4 million in 2023, then jumped by 85.01% to -$215000.0 in 2024, then surged by 65561.86% to $140.7 million in 2025, then sank by 100.07% to -$101000.0 in 2026.
- Business Quant data shows KYTX's Cash from Financing Activities at -$101000.0 in Q1 2026, $140.7 million in Q4 2025, and $1.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 30.14 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 68.63 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 9,311.16 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -538.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -802.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 238.74 Mn |
| 10 | Kyverna Therapeutics | 440.57 Mn | 440.57 Mn | - | -101,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -101,000.00 |
| Mar 31, 2026 | -101,000.00 |
| Dec 31, 2025 | 140.74 Mn |
| Dec 31, 2025 | 140.74 Mn |
| Sep 30, 2025 | 1.49 Mn |
| Sep 30, 2025 | 1.49 Mn |
| Jun 30, 2025 | -649,000.00 |
| Jun 30, 2025 | -649,000.00 |
| Mar 31, 2025 | -414,000.00 |
| Mar 31, 2025 | -414,000.00 |
| Dec 31, 2024 | -215,000.00 |
| Dec 31, 2024 | -215,000.00 |
| Sep 30, 2024 | -152,000.00 |
| Sep 30, 2024 | -152,000.00 |
| Jun 30, 2024 | -569,000.00 |
| Jun 30, 2024 | -569,000.00 |
| Mar 31, 2024 | 338.05 Mn |
| Mar 31, 2024 | 338.05 Mn |
| Dec 31, 2023 | -1.43 Mn |
| Dec 31, 2023 | -1.43 Mn |